COVID-19: California, Midwest states clamp down again
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Mizuho Securities Reiterates Buy Rating on Pfizer (PFE)
November 12, 2020 8:22 AM ESTMizuho Securities analyst Vamil Divan reiterated a Buy rating and $44.00 price target on Pfizer (NYSE: PFE) following the company's COVID-19 vaccine data released on Monday. The COVID-19 data was eagerly anticipated by investors for obvious reasons.
The company has already secured commitments from... More
Pfizer (PFE) Reports Positive Results from Fifth Phase 3 Trial of Abrocitinib
November 11, 2020 6:46 AM ESTPfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE REGIMEN study. This 52-week study investigated abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200mg. Patients were randomized... More
